Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. Show more

Location: 60 First Street, Cambridge, MA, 02141, United States | Website: https://primemedicine.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.136B

52 Wk Range

$1.11 - $6.94

Previous Close

$6.37

Open

$6.42

Volume

3,275,241

Day Range

$5.75 - $6.56

Enterprise Value

1.207B

Cash

101.8M

Avg Qtr Burn

-24.98M

Insider Ownership

18.19%

Institutional Own.

44.38%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.